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 Insulin is often cited as a classic near perfectly inelastic good; for those living 
with Type-1 diabetes, antihyperglycemic medicines are the only thing standing between 
them and possible death, and they must be willing to pay for the medication regardless of 
the price. When researchers at the University of Toronto released the patent for insulin in 
1922, they asked for only $1 so that the medication would be available to as many people 
as possible; however, as insulin analogs and new biosimilar substitutes have been 
invented, the price of medications has increased substantially. While the rising cost of 
insulin has been well researched, many of these studies focus on nominal prices and 
mean spending across a period of time. Building on previous research, this study utilizes 
fixed effects regression and instrumental variables to specifically analyze how the 
passage of time has affected out-of-pocket spending on insulin to discover if these 
estimates over- or underestimate the true nature of price changes to diabetic patients’ out-
of-pocket prescription expenditures. 
 
Keywords: Econometrics, Fixed Effects Regression, Instrumental Variables, 








Western Kentucky University , Bowling Green, KY    May 2019 
B.S. in Finance/B.A. in Economics/B.A. in Chinese – Mahurin Honors College 
Honors Capstone: Investigating the Change in the Out-of-Pocket Cost of Insulin 
Over Time 
 





Mahurin Honors College, WKU      Aug. 2017- 
 CE/T Student Assistant      May 2019 
 
Chinese Flagship, WKU       Aug. 2016- 
Recruitment Student Assistant      Aug. 2017 
 
 
AWARDS & HONORS 
 
Summa Cum Laude, WKU, May 2019 
Scholar of the College, WKU, May 2019 
President’s List, WKU, Aug. 2015-May 2019 
Beta Gamma Sigma Golden Key, WKU, May 2019 
Beta Gamma Sigma Business Honors Society 






Beijing Normal University, Beijing, China     June 2017-  





Long, J. (2019, February). Investigating the Change in the Out-of-Pocket Cost of Insulin 
Over Time. Presented at the Kentucky Honors Roundtable Research Conference. 









List of Figures and Equations……………………………………………………………vii 











LIST OF FIGURES AND EQUAITONS 
 
 












LIST OF TABLES 
 
Table 1: Summary Statistics……………………………………………………………………….5 
Table 2: Original Model…………………………………………………………………………..10 
Table 3: Instrument Validity Tests……………………………………………………………….12 
Table 4: Instrumental Variables Model…………………………………………………………..13 





 When learning about price elasticity, insulin is often one of the classic examples 
of a near perfectly inelastic good. For those living with Type-1 diabetes, 
antihyperglycemic medicines are the only thing standing between them and possible 
death, and they must be willing to pay for the medication regardless of the price. In 2015, 
30.3 million Americans had diabetes, 1.25 million of which were Type-1 (ADA 2018b).  
When researchers at the University of Toronto released the patent for insulin in 
1922, they asked for only $1 so that the medication would be available to as many people 
as possible; as insulin analogs and new biosimilar substitutes have been invented, the 
price of medications has increased substantially. Estimates on these price increases range 
from doubling between 2000 and 2010 (Lipska 2014) to increasing by nearly 200% from 
2002 to 2013 (Hua 2016). Excess lifetime medical spending for people with diabetes is 
estimated to reach $124,600 for those diagnosed at age 40, with even higher estimates for 
those diagnosed at a younger age (Zhuo 2014). 
While the rising cost of insulin has been well researched, many of these studies 
focus on nominal prices and mean spending over across a period of time. Building on 
previous research, this study seeks to specifically analyze how the passage of time has 
affected out-of-pocket spending on insulin to discover if these estimates over- or 





II. LITERATURE REVIEW 
 The rising costs of insulin and other costs associated with diabetes are well 
documented. Zhuo et al. (2015) analyze how excess medical spending attributable to 
diabetes has changed from 1987 to 2010-2011. They find that of the $2790 increase in 
excess spending per person, 55% is due to prescription medication. Lipska et al. (2014) 
likewise find an increase in the median out-of-pocket spending for all types of insulin 
from $19 in 2000 to $36 in 2010. However, the study only analyzes privately insured 
patients and relies on unpublished working documents for data, bringing into question 
representativeness and validity of the data. 
The American Diabetes Association (ADA) estimates that inflation-adjusted 
economic costs of diabetes increased by 26% from 2012 to 2017, as well as diabetic 
patients having around 2.3 times higher expenditures compared to a similar non-diabetic 
patient (2018a). Hua et al. (2016) break down inflation-adjusted expenditures for insulin 
alongside other antihyperglycemic medications, while also considering the change in use 
of these products. They find that the mean price of insulin increased from $4.34 per 
milliliter in 2002 to $12.92 in 2013. The above all estimate large increases in the cost of 
insulin, but Luo, Avorn, and Kesselheim (2015) note that Medicare reimbursements for 
insulin have also risen exponentially to account for rising prescription costs and usage. 
These studies all contribute to the literature in unique ways, but each fail to 
consider one of several key aspects: insurance coverage status, the change in out-of-
pocket expenditures compared to total expenditures, and change over each year rather 
than cumulatively over a period. This study attempts to address these issues by using 
instrumental variables to account for insurance coverage status, running separate 
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regressions for total expenditures and out-of-pocket expenditures, and using an 
interaction between the use of insulin and a year count variable to estimate average yearly 




III. DATA SOURCES 
 The data for this study consists of full year consolidated data files from the 
Medical Expenditure Panel Survey (MEPS) for the years 2007-2016. This database is one 
of the most used sources in the health economics literature for data on cost, usage, 
payment method, and more for health-related expenditures. After accounting for 
observations where key variables such as age and insulin use were not recorded and 
limiting the sample to observations where the respondent (R) is over the age of 18, the 
observation set includes 249,297 observations as noted in the summary statistics in Table 
1. However, after taking the natural log of the key dependent variables, namely out-of-
pocket prescription expenditure measured by prescription expenditures paid by oneself or 
family and total prescription expenditure to normalize the data, some observations were 
not usable due to having recorded $0 of prescription expenditures in one or more of the 
key dependent variables, and thus being undefined after taking the natural log. To remedy 
this, expenditures for all observations were increased in value by $1 to ensure they are 
retained in the sample; values originally undefined are thus preserved as a value of 0 after 
taking the natural log. This increase is minimal as a change of less than .1% of the sample 
mean and does not noticeably affect the distribution of the dataset. 
In the second model used with Equations (3) and (4), not all respondents provided 
data for the potential instruments, so the observation counts for the model using whether 
the respondent’s employer offered insurance to any at the firm as an instrument and for 
whether the respondent’s firm has multiple locations as an instrument drop to 143,779 
and 142,302, respectively. The smaller samples are similar to the original, both in 
demographic characteristics and in expenditure distribution. Sample statistics for the 
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smaller samples can be found in Appendices A and B, respectively. Because the 
instruments proved to be unreliable, only the original model’s results are of significance. 
Table 1: Summary Statistics 
 (1) (2) (3) (4) (5) 
VARIABLES N mean sd min max 
      
Total Income 249,297 29,582 33,277 -204,643 731,653 
Total RX Expenditures 249,297 1,037 5,986 0 2.227e+06 
Total RX Expenditures Paid by 
Self/Family 
249,297 181.2 659.3 0 42,770 
Age 249,297 45.27 17.67 18 85 
Female 249,297 0.535 0.499 0 1 
Diabetic 249,297 0.0826 0.275 0 1 
Uses Insulin 249,297 0.0244 0.154 0 1 
Insurance Coverage 249,297 0.803 0.398 0 1 
Black 249,297 0.207 0.405 0 1 
White 249,297 0.712 0.453 0 1 
Hispanic 249,297 0.270 0.444 0 1 
Census Region 249,297 2.762 1.020 1 4 
Year 249,297 5.606 2.824 1 10 
Uses Insulin*Year 249,297 0.142 0.998 0 10 
Ln(RX Expenditures) 249,297 3.479 3.233 0 14.62 
Ln(RX Expenditures Paid by 
Self/Family) 
249,297 2.539 2.572 0 10.66 
Post ACA 249,297 0.715 0.451 0 1 
Insulin*ACA 249,297 0.0185 0.135 0 1 





IV. EMPIRICAL METHODS 
 For this study, two OLS regressions are run in each of the three models; the 
regressions are identical with only the dependent variables differing to compare nominal 
costs and out-of-pocket costs. First, total prescription expenditure is regressed to assess 
validity of the model compared to previous estimations, then prescription expenditure 
paid by self/family is analyzed to estimate the year-to-year change in the impact of 
insulin costs on patients. These variables are in logarithmic form, both to normalize the 
data and to put results in terms of percentages. The two regressions use the same set of 
controls including fixed effects for the year and region by including dummy variables for 
each year and region, leaving out one category respectively to avoid collinearity issues; 
standard errors were also clustered at the year level to accurately assess statistical 
significance. The independent variable of interest is an interaction term between the 
insulin use indicator and year to analyze whether excess medical expenditures due to 
insulin use, both out-of-pocket and total, are growing over time or shrinking. 
Three models were estimated to assess the change in out-of-pocket costs of 
insulin. The first is shown in Equations (1) and (2). This is the most parsimonious model, 
where insurance coverage was left out to avoid endogeneity problems or bias from 
instruments. In Equations (1) and (2), 𝛾 represents a set of control variables, 𝜑𝑖 
represents regional fixed effects, 𝜔𝑡 captures year fixed effects, and 𝜀𝑖𝑡 is the error term. 
𝛾 includes the following variables: R’s Age, R’s Total Income, Female Indicator, 
Diabetic Indicator, R reports as Black, R reports as White, and R reports as Hispanic. 
Expenses for other antihyperglycemic medications other than insulin injections or by 
modified diet as well as hospitalization fees and visits to medical professionals are 
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assumed as captured within the Diabetic Indicator variable so that 𝛽2 accurately 
represents only the effect of insulin on prescription expenditures. The Census Region 
variable is read as follows: 1 corresponds to the Northeast region, 2 to the Midwest, 3 to 
the South, and 4 to the West. The Year variable is encoded to 2007 set as 1 through 2016 
set as 10.  
Equation 1: 
ln(𝑅𝑋 𝐸𝑥𝑝𝑒𝑛𝑑𝑖𝑡𝑢𝑟𝑒𝑠) = 𝛽0 + 𝛽1𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 + 𝛽2𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 ∗ 𝑌𝑒𝑎𝑟 + 𝛾 + 𝜑𝑖 + 𝜔𝑡 + 𝜀𝑖𝑡 
Equation 2: 
 ln(𝑅𝑋 𝑃𝑎𝑖𝑑 𝑏𝑦 𝑆𝑒𝑙𝑓 𝑜𝑟 𝐹𝑎𝑚𝑖𝑙𝑦) = 𝛽0 + 𝛽1𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 + 𝛽2𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 ∗ 𝑌𝑒𝑎𝑟 + 𝛾 +
𝜑𝑖 + 𝜔𝑡 + 𝜀𝑖𝑡 
The second model uses Equations (3) and (4) with two separate instruments for 
the insurance coverage variable to show the estimation differences between the two 
instruments. To further refine the value of  𝛽2, a variable indicating the respondent’s 
insurance status was added. 
To avoid estimation error due to endogeneity from adverse selection, two 
instrumental variable models were estimated. Instrumentation is important to consider 
when there is potential for reverse causality or other confounding issues in the model. In 
this case, those who are likely have higher prescription expenditures may be more likely 
to seek out insurance to cover those expenses. Instrumentation relies on two assumptions: 
the instrument must be correlated with the independent variable, but not correlated with 
the dependent variable except through its association with the independent variable. This 
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process is illustrated in Figure 1. The instrument is then used to predict values of the 
independent variable, which are then used in the original model. 




The first instrument considered is whether or not the respondent’s firm offered 
insurance to anyone at the firm. The reasoning behind the first instrument is that if the 
respondent’s firm offers insurance to others at the firm, it is likely that there is some 
standardized coverage plan to which the respondent can then choose to subscribe to or 
not. This should directly affect the respondent’s insurance coverage status, but not the 
respondent’s prescription expenditures. The second potential instrument is whether the 
respondent’s firm has multiple locations. The reasoning behind the second instrument is 
that if the firm has multiple locations, it is likely to be a larger firm. The firm size should 
be directly correlated with the respondent’s access to insurance plans, but not with 
prescription expenditures. 
Equation 3: 
 ln(𝑅𝑋 𝐸𝑥𝑝𝑒𝑛𝑑𝑖𝑡𝑢𝑟𝑒𝑠) = 𝛽0 + 𝛽1𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 + 𝛽2𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 ∗ 𝑌𝑒𝑎𝑟 +
𝛽3𝐼𝑛𝑠𝑢𝑟𝑎𝑛𝑐𝑒 𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒̂ + 𝛾 + 𝜑𝑖 + 𝜔𝑡 + 𝜀𝑖𝑡  
 
 
𝑋෠ = 𝛾 + 𝜑𝑍 + 𝑢 
𝑌 = 𝛼 + 𝛽𝑋෠ + 𝜀 







 ln(𝑅𝑋 𝑃𝑎𝑖𝑑 𝑏𝑦 𝑆𝑒𝑙𝑓 𝑜𝑟 𝐹𝑎𝑚𝑖𝑙𝑦) = 𝛽0 + 𝛽1𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 + 𝛽2𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 ∗ 𝑌𝑒𝑎𝑟 +
𝛽3𝐼𝑛𝑠𝑢𝑟𝑎𝑛𝑐𝑒 𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒̂ + 𝛾 + 𝜑𝑖 + 𝜔𝑡 + 𝜀𝑖𝑡  
The third model uses the implementation of the Affordable Care Act (ACA) as a 
source of variation to further examine the change in the cost of insulin. This model uses 
Equations (5) and (6). In this model, the dependent variable of interest is the interaction 
between the insulin use indicator and the post-ACA indicator to specifically assess the 
change in costs associated with insulin use after the implementation of the ACA. The 
fixed effects are left out of this model so that the only time related variable is the ACA 
dummy. 
Equation 5: 
 ln(𝑅𝑋 𝐸𝑥𝑝𝑒𝑛𝑑𝑖𝑡𝑢𝑟𝑒𝑠) = 𝛽0 + 𝛽1𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 + 𝛽2𝐴𝐶𝐴 + 𝛽3𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 ∗ 𝐴𝐶𝐴 + 𝛾 + 𝜀𝑖𝑡 
Equation 6: 
 ln(𝑅𝑋 𝑃𝑎𝑖𝑑 𝑏𝑦 𝑆𝑒𝑙𝑓 𝑜𝑟 𝐹𝑎𝑚𝑖𝑙𝑦) = 𝛽0 + 𝛽1𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 + 𝛽2𝐴𝐶𝐴 + 𝛽3𝑈𝑠𝑒𝑠 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 ∗






 Table 2 displays abridged results for both regressions with Equation (1) in the 
Column 1 and Equation (2) in Column 2 to show only the main variables of interest; 
outputs for the full regression can be found in Appendix C.  
Table 2: Original Model 
 (1) (2) 
VARIABLES Ln(RX 
Expenditures) 
Ln(RX Expenditures Paid by Self/Family) 
   
Uses Insulin 1.040*** 1.138*** 
 (0.0572) (0.0876) 
Uses Insulin*Year 0.0605*** -0.0547*** 
 (0.00781) (0.00955) 
Diabetic 2.346*** 1.689*** 
 (0.0217) (0.0427) 
Constant -0.432*** -0.504*** 
 (0.0279) (0.0495) 
   
Observations 249,297 249,297 
R-squared 0.317 0.302 
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
 
Equation (1) produces a statistically significant estimate of total prescription 
expenditures rising on average an additional 6.05% each year in the observed period for 
users of insulin relative to an average non-user of insulin, ceteris paribus. This aligns 
with current studies in assessing that the cost of insulin is rising exponentially year after 
year. There is also an economically and statistically significant coefficient on the insulin 
use indicator of 1.04, estimating that users of insulin are expected to pay 104% more in 
total prescription expenditures than non-insulin users as well as a coefficient of 2.346 on 
the diabetic indicator, supporting the fact that individuals with diabetes have over 200% 
higher prescription expenditures than non-diabetic individuals. Compared to the sample 
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mean for prescription expenditures of $1,037, an individual with diabetes who also takes 
insulin would have expenditures of $3,511. Equation (2), however, provides a story 
contrary to that told by most studies in the literature. While out-of-pocket prescription 
expenditures are still substantially higher for users of insulin, as seen 114% greater 
expenditures implied by the coefficient on the insulin use indicator variable, the 
interaction term has a coefficient of -0.0547 which is statistically significant at the 1% 
level, indicating that patients who use insulin injections may spend over 5% less out-of-
pocket for their prescriptions each year. This is also corroborated by the coefficients on 
the individual year dummy variables as they are all negative in sign and significant at the 
1% level. 
 To assess the validity of the two potential instruments, two regressions were run 
for each. The first regression is shown in Equation (7) and regresses the instrument on the 
insurance coverage variable to assess the first assumption of instrumentation: correlation 
between the instrument and the independent variable. The second regression, shown in 
Equation (8), tests the second assumption: lack of correlation between the instrument and 
the dependent variable. The results are shown in Table 3. While both instruments fail to 
fulfill the second assumption, the model is still estimated with the instruments as an 
exercise in instrumentation. Further research is required to find an appropriate instrument 
for insurance coverage.  
Equation 7: 





𝐿𝑛(𝑅𝑋 𝐸𝑥𝑝𝑒𝑛𝑑𝑖𝑡𝑢𝑟𝑒𝑠) = 𝛼 + 𝛽1𝐼𝑛𝑠𝑡𝑟𝑢𝑚𝑒𝑛𝑡 + 𝛾 + 𝜖 
Table 3: Instrument Validity Tests 









     
Employer Offers 
Insurance 
0.322*** 0.442***   




  0.106*** 0.257*** 
   (0.00331) (0.0176) 
Constant 0.508*** -0.616*** 0.632*** -0.455*** 
 (0.0195) (0.0581) (0.0135) (0.0580) 
     
Observations 143,779 143,779 142,302 142,302 





















Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
 
Table 4 shows results for Equations (3) and (4) using the two instruments for 
insurance coverage. The full regression results can be found in Appendix D. Columns 1 





Table 4: Instrumental Variables Model 











     
Insurancê  
Coverage 
1.374*** 1.223*** 2.431*** 1.732*** 
 (0.0590) (0.0504) (0.111) (0.0954) 
Uses Insulin 1.307*** 1.423*** 1.196*** 1.423*** 
 (0.0557) (0.131) (0.0639) (0.110) 
Uses 
Insulin*Year 
0.0472*** -0.0682*** 0.0626*** -0.0730*** 
 (0.0111) (0.0164) (0.0114) (0.0180) 
Diabetic 2.672*** 2.093*** 2.589*** 2.040*** 
 (0.0470) (0.0523) (0.0511) (0.0488) 
Constant -1.314*** -1.322*** -1.991*** -1.630*** 
 (0.0522) (0.0417) (0.0891) (0.0773) 
     
Observations 143,779 143,779 142,302 142,302 









Firm Has Multiple 
Locations 
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
 
 As before, the expected nominal prices paid for insulin are increasing, although at 
a slower predicted rate of 4.72% as seen in the coefficient on the interaction term. 
Column 2 corroborates the evidence from the earlier model, but with a larger coefficient 
on the interaction term, implying that out-of-pocket insulin costs are declining at a rate of 
6.82% per year. This estimate is again significant at the 1% level. The second instrument 
is consistent with the original model and with the first instrument. Nominal expenditures 
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are increasing at a rate of 6.26% per year, while out-of-pocket costs are decreasing 7.3% 
per year. These estimates are also significant at the 1% level. However, these estimates 
are biased due to the flaws in the instrumentation. A result of this bias is also evident in 
the coefficients on the predicted insurance coverage variables. While an increase in 
expenditures from insurance coverage could be explained by the concept of moral hazard, 
where protection from risk or costs encourages additional risky or costly behavior. 
However, this would not likely explain such large estimates as having insurance 
predicting 100-200% increases in prescription expenditures. 
 Table 5 shows the results from the Affordable Care Act model which uses 
Equations (5) and (6). The full results can be found in Appendix E. 
Table 5: ACA Model 
 (1) (2) 
VARIABLES Ln(RX Expenditures) Ln(RX Expenditures Paid by Self/Family) 
   
Uses Insulin 1.202*** 0.951*** 
 (0.0450) (0.0503) 
Post ACA -0.220*** -0.348*** 
 (0.0121) (0.00993) 
Insulin*ACA 0.249*** -0.176*** 
 (0.0509) (0.0565) 
Diabetic 2.350*** 1.697*** 
 (0.0196) (0.0182) 
Constant -0.682*** -0.647*** 
 (0.0244) (0.0194) 
   
Observations 249,297 249,297 
R-squared 0.315 0.298 
Robust standard errors in parentheses 




 An interesting result of this model is that the coefficient on the interaction term in 
Column 1 is positive while the coefficient on the Post-ACA indicator is negative. 
Considering that the ACA was designed to lower the cost of health care for all covered 
individuals, a result implying that insulin users are paying more for prescriptions post-
ACA while others pay less seems counterintuitive. However, this increase in 
expenditures can also be interpreted as an increase in the demand for insulin which may 
be a result of lower costs or greater access to insulin after the implementation of the 
Affordable Care Act. Regardless, this paper does not attempt to evaluate the effectiveness 
of the ACA or directly measure its effect on medical expenditures. Rather, using the 
implementation of the policy as a source of variation and as a measure of time, the 
coefficient on the interaction term in Column 2 implies that insulin users are paying 
1.76% less out-of-pocket on prescriptions after the ACA was implemented. This estimate 





 When using total prescription expenditures as the dependent variable, estimates 
match up with the current literature on the idea that insulin prices are increasing at an 
alarming rate. The additional costs associated with using insulin and with diabetes in 
general are also very large, both in nominal terms and in out-of-pocket costs. However, 
this problem seems to be mitigated by some outside entity as out-of-pocket costs for 
insulin are decreasing over time at an average rate of over 5% each year. Comparing the 
coefficients on the interaction term between the two equations in each model corroborates 
a point made by Luo, Avorn, and Kesselheim (2015). If the cost of insulin is rising so 
rapidly, yet patients’ out-of-pocket costs are declining, not only are these increasing costs 
are being borne by insurance providers, both public and private, but they are becoming 
even larger due to the declining cost to end users. 
For public sources of insurance such as Medicare and Medicaid, this may mean 
further increases in the federal debt if the federal government is unable to find sustainable 
funding for these programs. For private insurance companies, this may mean either 
higher premiums for patients who require insulin, which could further exacerbate the risk 
that poses low-income diabetic patients, or lower profits for the insurance firms. There is 
also the possibility of an adverse selection problem where healthier policy holders 
switching companies or plans to those with less prescription coverage. This could also 
lead to higher premiums and co-pays for diabetic patients, as well as, in the most extreme 
scenario, what is known as a death spiral, in which the pool of insurance policy holders 
progressively becomes less and less healthy as those who need insurance less leave the 
policy due to increasing rates. This, in turn, requires an increase in the cost of the 
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insurance to those remaining which then continues the cycle until only those who need 
insurance the very most will be willing to stay and are then struck with astronomical 
insurance costs. While out-of-pocket costs for insulin seemingly falling over time may be 
a benefit to insulin users in the short term, this could lead to serious issues in how 





 (1) (2) (3) (4) (5) 
VARIABLES N mean sd min max 
      
Total Income 143,779 38,777 35,412 -186,193 731,653 
Total RX Expenditures 143,779 607.1 6,576 0 2.227e+06 
Total RX Expenditures Paid by 
Self/Family 
143,779 130.4 545.8 0 38,560 
Age 143,779 40.77 13.73 18 85 
Female 143,779 0.490 0.500 0 1 
Diabetic 143,779 0.0516 0.221 0 1 
Uses Insulin 143,779 0.0130 0.113 0 1 
Insurance Coverage 143,779 0.811 0.391 0 1 
Employer Offers Insurance 143,779 0.688 0.463 0 1 
Black 143,779 0.195 0.396 0 1 
White 143,779 0.721 0.449 0 1 
Hispanic 143,779 0.279 0.448 0 1 
Census Region 143,779 2.772 1.015 1 4 
Year 143,779 5.610 2.851 1 10 
Uses Insulin*Year 143,779 0.0755 0.730 0 10 
Ln(RX Expenditures) 143,779 2.904 2.993 0 14.62 
Ln(RX Expenditures Paid by 
Self/Family) 
143,779 2.221 2.442 0 10.56 
Post ACA 143,779 0.711 0.453 0 1 
Insulin*ACA 143,779 0.00986 0.0988 0 1 
      
 
Appendix B 
 (1) (2) (3) (4) (5) 
VARIABLES N mean sd min max 
      
Total Income 142,302 37,961 34,542 -186,193 731,653 
Total RX Expenditures 142,302 586.8 2,738 0 238,050 
Total RX Expenditures Paid by 
Self/Family 
142,302 127.8 538.2 0 38,560 
Age 142,302 40.28 13.70 18 85 
Female 142,302 0.506 0.500 0 1 
Diabetic 142,302 0.0508 0.220 0 1 
Uses Insulin 142,302 0.0127 0.112 0 1 
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Insurance Coverage 142,302 0.812 0.390 0 1 
Firm has Multiple Locations 142,302 0.655 0.475 0 1 
Black 142,302 0.203 0.402 0 1 
White 142,302 0.715 0.452 0 1 
Hispanic 142,302 0.272 0.445 0 1 
Census Region 142,302 2.761 1.012 1 4 
Year 142,302 5.606 2.839 1 10 
Uses Insulin*Year 142,302 0.0738 0.721 0 10 
Ln(RX Expenditures) 142,302 2.920 2.988 0 12.38 
Ln(RX Expenditures Paid by 
Self/Family) 
142,302 2.222 2.433 0 10.56 
Post ACA 142,302 0.712 0.453 0 1 
Insulin*ACA 142,302 0.0096
1 
0.0976 0 1 
      
 
Appendix C 
 (1) (2) 
VARIABLES Ln(RX 
Expenditures) 
Ln(RX Expenditures Paid by Self/Family) 
   
Uses Insulin 1.040*** 1.138*** 
 (0.0572) (0.0876) 
Uses Insulin*Year 0.0605*** -0.0547*** 
 (0.00781) (0.00955) 
Total Income 1.44e-07 3.38e-06*** 
 (3.52e-07) (2.76e-07) 
Age 0.0687*** 0.0532*** 
 (0.000525) (0.000546) 
Female 0.812*** 0.598*** 
 (0.0167) (0.0344) 
Diabetic 2.346*** 1.689*** 
 (0.0217) (0.0427) 
Black 0.361*** 0.166*** 
 (0.0303) (0.0226) 
White 1.014*** 0.871*** 
 (0.0178) (0.0176) 
Hispanic -1.147*** -0.942*** 
 (0.0187) (0.0257) 
Census Region = 2 0.00895 0.162*** 
 (0.0186) (0.0204) 
Census Region = 3 -0.118*** 0.123*** 
 (0.0364) (0.0190) 
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Census Region = 4 -0.299*** -0.148*** 
 (0.0226) (0.0234) 
Year = 2 -0.0574*** -0.112*** 
 (0.00103) (0.00120) 
Year = 3 -0.134*** -0.261*** 
 (0.00156) (0.00138) 
Year = 4 -0.281*** -0.335*** 
 (0.00133) (0.00107) 
Year = 5 -0.341*** -0.345*** 
 (0.00157) (0.00138) 
Year = 6 -0.442*** -0.440*** 
 (0.00209) (0.00216) 
Year = 7 -0.278*** -0.461*** 
 (0.00266) (0.00256) 
Year = 8 -0.247*** -0.531*** 
 (0.00244) (0.00217) 
Year = 9 -0.196*** -0.572*** 
 (0.00211) (0.00238) 
Year = 10 -0.232*** -0.662*** 
 (0.00224) (0.00278) 
Constant -0.432*** -0.504*** 
 (0.0279) (0.0495) 
   
Observations 249,297 249,297 
R-squared 0.317 0.302 
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
 
Appendix D 











     
Insurance 
Coverage 
1.374*** 1.223*** 2.431*** 1.732*** 
 (0.0590) (0.0504) (0.111) (0.0954) 
Uses Insulin 1.307*** 1.423*** 1.196*** 1.423*** 
 (0.0557) (0.131) (0.0639) (0.110) 
Uses 
Insulin*Year 
0.0472*** -0.0682*** 0.0626*** -0.0730*** 
 (0.0111) (0.0164) (0.0114) (0.0180) 
Total Income 1.96e-06*** 2.04e-06*** -3.77e-07 8.93e-07** 
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 (3.17e-07) (3.31e-07) (4.27e-07) (4.51e-07) 
Age 0.0530*** 0.0456*** 0.0516*** 0.0449*** 
 (0.000622) (0.000403) (0.000688) (0.000542) 
Female 0.913*** 0.658*** 0.825*** 0.610*** 
 (0.0170) (0.0348) (0.0174) (0.0337) 
Diabetic 2.672*** 2.093*** 2.589*** 2.040*** 
 (0.0470) (0.0523) (0.0511) (0.0488) 
Black 0.279*** 0.151*** 0.257*** 0.131*** 
 (0.0245) (0.0230) (0.0274) (0.0229) 
White 0.991*** 0.807*** 0.948*** 0.774*** 
 (0.0198) (0.0205) (0.0193) (0.0195) 
Hispanic -0.846*** -0.636*** -0.638*** -0.533*** 
 (0.0202) (0.0277) (0.0302) (0.0295) 
Census 
Region = 2 
0.0891*** 0.167*** 0.105*** 0.176*** 
 (0.0312) (0.0253) (0.0338) (0.0267) 
Census 
Region = 3 
0.0449 0.212*** 0.123*** 0.249*** 
 (0.0288) (0.0131) (0.0416) (0.0221) 
Census 
Region = 4 
-0.228*** -0.132*** -0.221*** -0.128*** 
 (0.0348) (0.0324) (0.0444) (0.0360) 
Year = 2 -0.0560*** -0.108*** -0.0484*** -0.104*** 
 (0.000939) (0.000906) (0.000858) (0.000933) 
Year = 3 -0.103*** -0.177*** -0.116*** -0.190*** 
 (0.00121) (0.00118) (0.00117) (0.00115) 
Year = 4 -0.244*** -0.273*** -0.244*** -0.274*** 
 (0.00142) (0.00106) (0.00181) (0.00155) 
Year = 5 -0.308*** -0.283*** -0.293*** -0.277*** 
 (0.00168) (0.00142) (0.00186) (0.00178) 
Year = 6 -0.414*** -0.378*** -0.396*** -0.368*** 
 (0.00231) (0.00202) (0.00325) (0.00306) 
Year = 7 -0.270*** -0.358*** -0.266*** -0.365*** 
 (0.00278) (0.00232) (0.00370) (0.00332) 
Year = 8 -0.338*** -0.526*** -0.369*** -0.543*** 
 (0.00279) (0.00297) (0.00344) (0.00354) 
Year = 9 -0.305*** -0.572*** -0.364*** -0.609*** 
 (0.00412) (0.00433) (0.00607) (0.00580) 
Year = 10 -0.367*** -0.673*** -0.439*** -0.715*** 
 (0.00498) (0.00506) (0.00663) (0.00647) 
Constant -1.314*** -1.322*** -1.991*** -1.630*** 
 (0.0522) (0.0417) (0.0891) (0.0773) 
     
Observations 143,779 143,779 142,302 142,302 
R-squared 0.254 0.239 0.232 0.220 








Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
 
Appendix E 
 (1) (2) 
VARIABLES Ln(RX Expenditures) Ln(RX Expenditures Paid by Self/Family) 
   
Uses Insulin 1.202*** 0.951*** 
 (0.0450) (0.0503) 
Post ACA -0.220*** -0.348*** 
 (0.0121) (0.00993) 
insulin*ACA 0.249*** -0.176*** 
 (0.0509) (0.0565) 
Total Income 1.18e-07 3.05e-06*** 
 (1.76e-07) (1.46e-07) 
Age 0.0687*** 0.0530*** 
 (0.000314) (0.000257) 
Female 0.813*** 0.596*** 
 (0.0109) (0.00877) 
Diabetic 2.350*** 1.697*** 
 (0.0196) (0.0182) 
Black 0.444*** 0.271*** 
 (0.0209) (0.0164) 
White 1.087*** 0.958*** 
 (0.0192) (0.0151) 
Hispanic -1.208*** -1.017*** 
 (0.0132) (0.0105) 
Constant -0.682*** -0.647*** 
 (0.0244) (0.0194) 
   
Observations 249,297 249,297 
R-squared 0.315 0.298 
Robust standard errors in parentheses 






American Diabetes Association (2018a). Economic Costs of Diabetes in the U.S. in 2017. 
Diabetes Care, 41(5), 917-928. https://doi.org/10.2337/dci18-0007 
American Diabetes Association (2018b). Statistics About Diabetes. Retrieved from 
http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav 
Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and Prices 
of Antihyperglycemic Medications in the United States: 2002-
2013. JAMA. 2016;315(13):1400–1402. doi:10.1001/jama.2016.0126 
Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND. Use and Out-of-
Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 
2010. JAMA. 2014;311(22):2331–2333. doi:10.1001/jama.2014.6316 
Luo J, Avorn J, Kesselheim AS. Trends in Medicaid Reimbursements for Insulin From 
1991 Through 2014. JAMA Intern Med. 2015;175(10):1681–1687. 
doi:10.1001/jamainternmed.2015.4338 
Medical Expenditure Panel Survey (2009). Survey Background. Retrieved from 
https://meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp 
Meer, J., & Rosen, H. (2004). Insurance and the utilization of medical services. Social 
Science & Medicine, 58, 1623-1632. doi: 10.1016/S0277-9536(03)00394-0 
Zhuo, X., Zhang, P., Barker, L., Albright, A., Thompson, T. J., & Gregg, E. (2014). The 
Lifetime Cost of Diabetes and Its Implications for Diabetes Prevention. Diabetes 
Care, 37(9), 2557-2564. https://doi.org/10.2337/dc13-2484 
24 
 
Zhuo, X., Zhang, P., Kahn, H. S., Bardenheier, B. H., Li, R., & Gregg, E. W. (2015). 
Change in Medical Spending Attributable to Diabetes: National Data from 1987 
to 2011. Diabetes Care, 38(4), 582-587. https://doi.org/10.2337/dc14-1687 
